AnaptysBio sues Tesaro and GSK for breach of Jemperli collaboration; countersuit filed

ANAPTYSBIO, INC

AnaptysBio alleges Tesaro breached exclusivity by conducting trials with competing PD-1 antagonists (e.g., Keytruda) and failing to maximize Jemperli return.
Tesaro countersued AnaptysBio on Nov 20, 2025, seeking injunctive relief; AnaptysBio calls claims meritless and will seek dismissal.
Parties agreed to expedited Delaware Chancery Court schedule; trial anticipated July 2026.
Milestone and royalty payments under Collaboration Agreement remain due during litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.